Abstract
Thalidomide is emerging as a potentially important therapeutic option in the treatment of metastatic prostate cancer. Although the mechanism of action of this agent remains elusive in malignancies of the prostate, recent data has indicated that thalidomide may play a role in inflammation, immunomodulation, and anti-angiogenesis. Lenalidomide (CC-5013), a thalidomide analogue with improved activity and safety profile in certain disease contexts, is in the early stages of development in prostate cancer. This review will provide the current status of the history, mechanism, metabolism, and clinical use of thalidomide in metastatic prostate cancer. It will also describe the mechanism and clinical use of lenalidomide as it pertains to malignancies of the prostate.
Keywords: Prostate cancer, thalidomide, lenalidomide, CC-5013, angiogenesis inhibition
Anti-Cancer Agents in Medicinal Chemistry
Title: Current Status of Thalidomide and CC-5013 in the Treatment of Metastatic Prostate Cancer
Volume: 9 Issue: 10
Author(s): Tristan M. Sissung, Silja Thordardottir, Erin R. Gardner and William D. Figg
Affiliation:
Keywords: Prostate cancer, thalidomide, lenalidomide, CC-5013, angiogenesis inhibition
Abstract: Thalidomide is emerging as a potentially important therapeutic option in the treatment of metastatic prostate cancer. Although the mechanism of action of this agent remains elusive in malignancies of the prostate, recent data has indicated that thalidomide may play a role in inflammation, immunomodulation, and anti-angiogenesis. Lenalidomide (CC-5013), a thalidomide analogue with improved activity and safety profile in certain disease contexts, is in the early stages of development in prostate cancer. This review will provide the current status of the history, mechanism, metabolism, and clinical use of thalidomide in metastatic prostate cancer. It will also describe the mechanism and clinical use of lenalidomide as it pertains to malignancies of the prostate.
Export Options
About this article
Cite this article as:
Sissung M. Tristan, Thordardottir Silja, Gardner R. Erin and Figg D. William, Current Status of Thalidomide and CC-5013 in the Treatment of Metastatic Prostate Cancer, Anti-Cancer Agents in Medicinal Chemistry 2009; 9 (10) . https://dx.doi.org/10.2174/187152009789735017
DOI https://dx.doi.org/10.2174/187152009789735017 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Marizomib, A Potent Second Generation Proteasome Inhibitor from Natural Origin
Anti-Cancer Agents in Medicinal Chemistry Acute and Chronic Stress-Induced Disturbances of Microglial Plasticity, Phenotype and Function
Current Drug Targets Understanding Molecular Pathways and Targets of Brachyury in Epithelial-mesenchymal Transition (EMT) in Human Cancers
Current Cancer Drug Targets Biosimilars: Current Scientific and Regulatory Considerations
Current Clinical Pharmacology IL-24: Physiological and Supraphysiological Effects on Normal and Malignant Cells
Current Medicinal Chemistry The Role of Insulin-Like Growth Factor I Components in the Regulation of Vitamin D
Current Pharmaceutical Biotechnology Nonsteroidal Anti-Inflammatory Drugs: Exploiting Bivalent COXIB/ TP Antagonists for the Control of Cardiovascular Risk
Current Medicinal Chemistry Pharmaceutical Nanotechnology United States Patent Watch (April – June 2015)
Pharmaceutical Nanotechnology Mitochondria as Therapeutic Targets of Estrogen Action in the Central Nervous System
Current Drug Targets - CNS & Neurological Disorders Doxycycline as Potential Anti-cancer Agent
Anti-Cancer Agents in Medicinal Chemistry Fluorescein Fluorescence Use in the Management of Intracranial Neoplastic and Vascular Lesions: A Review and Report of a New Technique
Current Drug Discovery Technologies Editorial [Hot Topic: ADAMs: Targets for Drug Discovery (Executive Editor: Marcia L. Moss)]
Current Pharmaceutical Design DNA Methylation: A Possible Target for Current and Future Studies on Cancer?
Epigenetic Diagnosis & Therapy (Discontinued) Modes of Action of Arjunolic Acid and Derivatives on Trypanosoma cruzi Cells
Current Topics in Medicinal Chemistry Interferon Therapy in Lung Cancer: Current Perspectives
Current Cancer Therapy Reviews The Brain-Immune-Gut Triangle: Innate Immunity in Psychiatric and Neurological Disorders
Current Immunology Reviews (Discontinued) Is there a Possible Single Mediator in Modulating Neuroendocrine–thymus Interaction in Ageing?
Current Aging Science Modulation of Potassium Channels as a Therapeutic Approach
Current Pharmaceutical Design Antiinflammatory Activity of Melatonin in Central Nervous System
Current Neuropharmacology NAD<sup>+</sup>-Dependent Enzymes at the Endoplasmic Reticulum
Current Topics in Medicinal Chemistry